An Evidence-Based Argument Is Often the Fastest Route to Immunotherapy Authorization

Randy Dotinga
Published: Tuesday, Apr 30, 2019
Ezra Cohen, MD

Ezra Cohen, MD

Ezra Cohen, MD, prescribes immunotherapy (I/O) just about every day. He is a specialist in head and neck cancer, for which multiple I/O drugs have been approved. Usually, he said, getting payers to approve treatment is simple. But not always, and sometimes he needs to step in to make the case for his patient. That is especially true when it comes to off-label uses. “There are cancers I treat where I believe [I/O] could be effective but there is not an FDA approval,” said Cohen, codirector of the San Diego Center for Precision Immunotherapy and associate director of Translational Science at Moores Cancer Center at University of California, San Diego. “That’s where the challenges start to come in. We need to work at it.”
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication